Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine vs Treatment Choice in MDS/CMML (ASTRAL-3)
NCT02907359Phase 3Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 14
01
Overview
A Phase 3 trial of guadecitabine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Astex Pharmaceuticals. Started Jan 2017; status: completed.
02
Drugs
guadecitabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02907359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907359.